Patricio Massera was appointed Chief Executive Officer of AGC Biologics (formerly CMC Biologics) in May 2019. Patricio joined the company in 2012, as General Manager of Copenhagen-based CMC Biologics A/S. He later served as Chief Operating Officer in the Seattle-based company headquarters. As CEO, Patricio quickly developed a comprehensive people management strategy, recognizing that with a healthy company culture and highly engaged employees, AGC is best positioned to provide the highest-quality services to our customers. Across his 20 years of biologics experience, Patricio held several key executive positions at MSD AH, Intervet/Schering-Plough, Biogenesis-Bagó and other biotech companies in Spain, Brazil, and Argentina. With a background in biochemistry and business, Patricio has acted as a change agent in several integration processes and cultivated strong leadership teams, dedicated to developing, manufacturing, and controlling biotechnological products and vaccines for human and animal health.
Patricio holds an MBA from UCEMA and a Biochemist degree from the University of Buenos Aires.
Vijay Raghavan became the Chief Financial Officer for AGC Biologics in January 2020. Vijay joined the company as Senior Vice President of Global Finance in April 2018, and has been a dedicated member and leader of the team, driving organizational growth through strategic financial planning, treasury, reporting and accounting. As CFO, Vijay continues to build value for the company, ensuring that AGC Biologics optimizes resource use to support the health and growth of our company and our customers. Vijay joined AGC Biologics after several years working in finance leadership roles at Cray and Microsoft. He leverages his 25 years of progressive experience in accounting, finance, business partnerships, strategic planning, and reporting for companies ranging from startups to conglomerates.
Outside of work, Vijay is dedicated to community service, including leadership positions at Hopelink and the Indian Association of Western Washington. Vijay earned a Masters of Commerce, Accounting, and Banking from the University of Madras in India, and an M.B.A. from the University of Hartford.
Kasper Møller was appointed to the role of Chief Technical Officer in June 2019, after serving for two years as General Manager and Site Head for our Copenhagen facility. Throughout his 14 years at AGC Biologics, Kasper has provided expertise in process characterization and validation, in previous roles such as Principal Scientist, Department Manager within Process Development, Vice President of Process Development and Vice President of Manufacturing. Earlier in his career, Kasper spent five years as an assistant professor and faculty member at the Technical University of Denmark, conducting research, and teaching fermentation technology and metabolic engineering.
Kasper earned a Ph.D. in Biochemical Engineering, with a focus on microbial physiology, from the Technical University of Denmark. He pursued his post-doc at the university’s Center for Process Biotechnology, as well as the Department of Genetics at Washington University Medical School in St. Louis. Along the way, he contributed to more than a dozen scientific international journals and publications.
Jean-Baptiste ("JB") Agnus was appointed to the role of Chief Business Officer at AGC Biologics in November 2021. He brings more than 20 years of experience in the biopharmaceutical and CDMO spaces and has spent his career helping build and shape successful companies. Just prior to joining AGC Biologics, JB spent three years with Ajinomoto Bio-Pharma Services, where he served as Vice President of Sales and Marketing on the global leadership team. Prior to that, he spent 13 years at Novasep, where he held a number of business development leadership roles, including Head of Sales & Business Development, North America, where he led small molecule API and biologics contract manufacturing services.
JB earned his Master of Science, Organic Chemistry from Université Paul Sabatier Toulouse III and holds a second Master, Process Engineering from École centrale de Marseille.
Daisy Szabo, Executive Vice President of Human Resources, joined AGC Biologics in April 2017, and is responsible for strategic business alignment, process improvement for restructuring and growth, talent acquisition, change management, and operational excellence. Daisy brings more than 18 years of strategic experience, across industries including financial services, high-tech, and power generation, in environments ranging from startups to Fortune 100 companies, across Asia and the Americas. Daisy takes a cross-cultural approach to cultivating a workforce, having owned her own company in the apparel industry import distribution.
Daisy is a board member for Open Doors USA. She earned her Bachelor’s of Commerce from McGill University, and a Master of Business Administration from Azusa Pacific University. She completed the Executive Education program at University of Washington's Foster School of Business.
As Executive Vice President, Global Quality, Paul Tsang is accountable for the company’s pharmaceutical quality system across the manufacturing network. Having joined CMC Biologics in 2015 as Vice President, US Quality, he became a member of the AGC Biologics executive team in 2017 and led the successful integration of quality systems across the three companies that became AGC Biologics. Paul brings nearly 30 years of experience in the CMC development and commercialization of numerous protein and small-molecule products. His expertise includes specification development, product comparability and regulatory strategy. Prior to joining the company, he held positions of increasing responsibility at Amgen and Eli Lilly in Operations, Quality and Analytical Development roles at the site, corporate and global level.
Paul is involved in our community and industry. He is the life sciences sector representative on the Business & Philanthropy Leadership Committee for the governor’s Career Connect Washington initiative. He earned a Ph.D. in chemistry from Texas A&M University and a Bachelor of Science in applied chemistry from Harvey Mudd College.
Hiroshi Nishimura was appointed Senior Vice President, Corporate and Strategic Planning, in January 2020 after 33 years with AGC Inc. Prior to his recent appointment, Hiroshi served as Chief Financial Officer of AGC Biologics operations at the Seattle-based company headquarters for two years. Since joining Asahi Glass Company (now AGC Inc.), he has been engaged in a variety of assignments, including purchasing, sales of architectural glass, and corporate planning. In the late 90’s, Hiroshi pivoted toward sales operations in the U.S., with a focus on glass products imported from Japan. In 2016, Hiroshi joined our Life Science team as a leader of Planning and Accounting Management. With a focus on driving strategic business initiatives and fostering relationships with AGC headquarters, Hiroshi remains a vital part of the organization.
Hiroshi began his career by earning a bachelor’s degree in law from Tokyo University.
Greg Shelton – General Counsel and Corporate Secretary
After joining AGC Biologics as Global Vice President Legal Affairs in July of 2021, Greg Shelton was appointed to the Executive Leadership Team as General Counsel and Corporate Secretary on April 1, 2022. Greg brings more than 25 years of experience and legal expertise in the pharmaceutical, biotech, medical device and healthcare spaces. Before joining AGC Biologics, Greg served as Division Counsel and Senior Leadership Team member for Stryker Emergency Care – a $1.1 billion division of Stryker Corporation. Prior to Stryker, Greg represented a notable roster of multi-national companies at high-performing law firms in both Seattle and New York City. He also holds author’s credit within numerous legal publications.
Greg earned his Bachelor of Art, Philosophy from University of Massachusetts and his Juris Doctor from Vermont Law School.
Kevin Ingham — General Manager, Seattle Facility
Kevin Ingham, General Manager of the Seattle facility, joined AGC Biologics in August 2021 after more than two years as Site Head/Executive Director of Drug Product Manufacturing for Switzerland-based Roche. With nearly two decades of industry experience, Kevin began his career at Genentech. His early days on the manufacturing floor heavily influenced who he is as a leader. From Manufacturing Technician, to Engineer, to Manager of Drug Product Manufacturing and finally Director of Drug Product Manufacturing, he has a firm understanding of the needs of the customer as well as how to effectively support the Seattle team.
Kevin earned his Bachelor of Science in Geophysics from UC Santa Barbara and he obtained his Master of Science in Industrial and Systems Engineering from San Jose State University while working the night shift on the manufacturing floor. His positive outlook and attributes will serve AGC Biologics well as Kevin assumes responsibility for the financial health, manufacturing achievements, and culture of our Seattle site.
Andrea C. Porchia — General Manager, Copenhagen Facility
Andrea C. Porchia, General Manager of the Copenhagen facility, joined AGC Biologics in August 2013. During her time with the company, she has taken on increasing responsibility across sites in progressive roles as Project Director, Senior Director Business Development, and Global Vice President of Project Management prior to the GM appointment. Andrea’s deep knowledge of the Copenhagen site is complemented by a track record of successful integration and standardization of project management practices across sites at AGC Biologics. With more than 20 years of experience in CMC development, her expertise includes process and analytical development, tech transfer, drug substance and drug product manufacturing and regulatory strategy.
Andrea pursued her education in Argentina and Denmark. She earned a PhD in Biochemistry from Mar del Plata University, Buenos Aires, Argentina, in addition to a Postdoctoral position from The Royal Veterinary and Agricultural University, Copenhagen, Denmark.
As the General Manager of the Heidelberg facility, Dieter Kramer applies two decades of technical and leadership expertise. Dieter joined AGC Biologics in July 2018, having worked in a similar role at Corden Biochem GmbH, a full-service Contract Manufacturing Organization. Dieter brings breadth and depth to his role. Combining the disciplines of business and chemical engineering, he held various positions in R&D, manufacturing, project management and general management in the Sandoz/Novartis network in Austria and Germany. In particular, he spent five years as Managing Director of an API manufacturing site with large-scale fermentation and downstream capabilities.
Dieter pursued his education in Austria. He earned a Master of Business Administration from Management Center Innsbruck. He received his master’s degree in Technical Chemistry and Biotechnology at the Technical University of Graz. He completed his education at Höhere Technische Bundeslehranstalt in Wels with advanced study in chemical engineering.
Jun Takami — General Manager, Chiba Facility
Jun Takami, General Manager of AGC Biologics’ facility in Chiba, joined AGC Inc. in 2017 and has since served two years as the Project Management Director at our Japan site. Jun brings over 15 years of experience in the pharmaceutical industry with roles in process development, GMP manufacturing, process engineering and PLI activities with Roche group at Chugai Pharmaceuticals.
Jun Takami holds master in biological science from Kobe University as well as a bachelor’s degree.
Luca Alberici, General Manager of the Milan, Italy facility is a value driven professional who came to AGC Biologics through the July 2020 acquisition of MolMed, a leading cell and gene therapy company. His rich educational background is complemented by more than 14 years of industry experience in roles of increasing responsibility for strategic business development and operations, licensing, project management and intellectual property for large molecule and specialty drug development and commercialization. Throughout his career, Luca has been fundamental in licensing and strategic supply agreements that drove top line results in his former position as Chief Business Officer at MolMed. In addition to practical proficiency with discovery and development for HIV and tumor therapies in his early career, Luca has extensive experience in negotiating go-to-market strategies and bringing new cell and gene therapies to market through partnerships with leading biopharmaceutical companies.
Luca earned a PhD and Masters in cellular and molecular biology from Libera Università Vita-Salute San Raffaele, in addition to a Master of Business Administration (MBA) from SDA Bocconi. He has a thorough understanding of European regulatory requirements and pricing policies, and is a published author and frequent industry speaker.
Regina Choi-Rivera — General Manager, Boulder Facility
Regina Choi-Rivera, General Manager of the Boulder, Colorado facility joined AGC Biologics in 2022 and brings over 25 years of experience in the biotech industry – most recently serving as Vice President, Head of Drug Product Business Unit for Samsung Biologics. Regina has leveraged her academic background in Chemical Engineering to design, build and lead Drug Substance (DS) and Drug Product (DP) manufacturing facilities with great success. She also brings a deep understanding of project management in the biopharmaceutical industry, having launched and scaled a Project Management system as a PM Head – all while overseeing numerous tech transfer projects and a team of project managers.
Regina holds both a Master of Engineering (MEng) and Bachelor of Engineering (BE) in Chemical Engineering from The Cooper Union for the Advancement of Science and Art, in addition to a PMP designation from the Project Management Institute. With an innate ability to streamline complex challenges, Regina will serve both the AGC Biologics Boulder team and their large-scale customers in future growth.
Tony Fraij, General Manager of the Longmont, Colorado facility is an industry veteran with deep technical expertise who came to AGC Biologics through the August 2021 acquisition of the former Novartis site in Longmont, a state of the art viral vector and gene therapy facility. Tony has more than twenty years of industry experience through Engineering, Technical Operations and Executive Leadership roles around the world. His experience flexing between global and site based roles equips him with a unique perspective that enables him to draw alignment across an expansive organization like AGC Biologics.
Tony earned his Bachelor of Science in Packaging Science from Rochester Institute of Technology and he obtained his MBA from The Ohio State University. By leveraging his technical acumen and team first approach, AGC Biologics in Longmont will flourish under Tony’s leadership as he assumes responsibility for integrating the Longmont site into the AGC Biologics global network.